Complex genetic & medication information shouldn’t be hard to use.
Comprehensive Panel
EffectiveRX helps you create a holistic treatment plan based on your patient's genetics and best in class medication management tools
Call us at (800) 858-5909
Discover how EffectiveRX can assist you in getting your patients on the best medication(s) for them
Complex genetic & medication information shouldn’t be hard to use.
Comprehensive Panel
EffectiveRX helps you create a holistic treatment plan based on your patient's genetics and best in class medication management tools
Call us at (800) 858-5909
Discover how EffectiveRX can assist you in getting your patients on the best medication(s) for them
Complex genetic & medication information shouldn’t be hard to use
Our Medication Action Plan (MAP) combines appropriateness tools, PharmD expertise and genetic results to provide a clear, concise patient-centric MAP for treatment, including:
- Established Explicit Medication tools, including BEERs, Anticholinergic Burden, FDA Black Box Warnings, and more
- Published clinical and scientific data
- Genetic Results
- Lifestyle Factors
- Medication History & Potential Medications, including over-the-counter medications
- PharmD Expertise
The Pharmacogenomics Appraisal, Evidence Scoring and Interpretation System (PhAESIS) combines this information to create a holistic treatment plan. This is translated into EffectiveRX’s MAP Report.2
Personalized Medicine
No two people are alike.
Nor is their response to medication.
Do you have patients who are taking multiple medications and are struggling?
Polypharmacy increases the risk of adverse drug reactions caused by a patient’s genetics.1
The Impact of
Polypharmacy
Due to comorbidities in an aging population, polypharmacy is a prevalent challenge in long-term care facilities.3 Polypharmacy often results from comorbidities and has many other negative impacts, including:
PATIENTS
- Decreased Quality of Life
- Increased mobility issues
- Increased mortality
- Increased risk of disability, falls, frailty, inappropriate medication use, long-term care placement & Medication nonadherence 1
Providers
- Decreased physician functionality (workflow impairment, decreased quality of care)
- Decreased physician productivity
- Increased burden on the health care system
- Increased medication errors 1
Common reasons for prescribing
History of Medication Failures
Experienced adverse drug reaction or sensitivity to prescribed medication(s)
Medication Class is new to the patient
Desired medication for the patient has FDA warnings
An “Inhibitor” or “Inducer” may affect therapeutic response to prescribed medication
A component of medical decision making for which medication(s) to avoid, prescribe or titrate
Are your patients experiencing diminished efficacy and/or side effects from these current medications? Or are you considering a new therapy?*
Anticoagulants
Coumadin (warfarin)
Jantoven (warfarin)
Cardiology
Coreg (carvedilol)
Crestor (rosuvastatin)
FloLipid (simvastatin)
Lescol (fluvastatin)
Plavix (clopidogrel)
Rythmol (propafenone)
Zocor (simvastatin)
Dyskinesia
Austedo (deutetrabenazine)
Ingrezza (valbenazine)
Xenazine (tetrabenazine)
Gastroenterology
Antivert (meclizine)
Dexilant (dexlansoprazole)
Marinol (dronabinol)
Prilosec (omeprazole)
Prevacid (lansoprazole)
Protonix (pantoprazole)
Reglan (metoclopramide)
Zofran (ondansetron)
Gaucher's Disease
Cerdelga (eliglustat)
Immunology
Evoxac (cevimeline)
Prograf (tacrolimus)
Protopic (tacrolimus)
Infectious Disease
Reyataz (atazanavir)
Sustiva (efavirenz)
Vfend (voriconazole)
Neurology
Briviact (brivaracetam)
Dilantin (phenytoin)
Onfi (clobazam)
Xenazine (tetrabenazine)
Oncology
Adrucil (fluorouracil)
Balversa (erdafitinib)
Efudex (fluorouracil)
Fluoroplex (fluorouracil)
Iressa (gefitinib)
Pegasys (peginterferon alfa-2a)
Pegintron/Sylatron (peginterferon alfa-2b)
Soltamox (tamoxifen)
Tolak (fluorouracil)
Xeloda (capecitabine)
Pain Management
Ansaid (flurbiprofen)
Celebrex (celecoxib)
Chlortenoxicam (lornoxicam)
Codeine
Feldene (piroxicam)
Hydrocodone
Ibuprofen
Mobic (meloxicam)
Mobiflex (tenoxicam)
Ocufen (flurbiprofen)
Olinvyk (oliceridine)
Ultram (tramadol)
Psychiatry
Abilify (aripiprazole)
Adderall (amphetamine)
Anafranil (clomipramine)
Aristada (aripiprazole lauroxil)
Celexa (citalopram)
Clozaril (clozapine)
Effexor (venlafaxine)
Elavil (amitriptyline)
Fanapt (Iloperidone)
FazaClo (clozapine)
Lexapro (escitalopram)
Luvox (fluvoxamine)
Mellaril (thioridazine)
Norpramin (desipramine)
Orap (pimozide)
Pamelor (nortriptyline)
Paxil (paroxetine)
Rexulti (brexpiprazole)
Silenor (doxepin)
Strattera (atomoxetine)
Surmontil (trimipramine)
Tofranil (imipramine)
Trilafon (perphenazine)
Trintellix (vortioxetine)
Versacloz (clozapine)
Wakix (pitolisant)
Zoloft (sertraline)
Urology
Detrol (tolterodine)
The above medications have actionable gene-drug relationships according to CPIC Levels A&B as well as FDA recommendations.
Many additional medications are also reviewed, reported and categorized based on clinical evidence.
*An EffectiveRX Comprehensive test is intended as an aid to guide medication management decisions for patients who are prescribed to or under consideration for prescription medications associated with but not limited to cardiovascular health, psychiatry, pain management, addiction, or thrombophilia.
Comprehensive Test Panel
| Gene | Gene-Drug Interaction |
|---|---|
| CYP2C9 | CYP2C9 Gene-drug variant associations affecting drug response/metabolism include celecoxib, flurbiprofen, fosphenytoin ,ibuprofen, losartan, meloxicam, phenytoin, warfarin. (CPIC Level best drug: A/ PharmGKB Level Best drug:1A) ) PharmGKB Web site. http://Clinical Guideline Annotations (pharmgkb.org). Accessed November 2nd, 2022.Ref: 37, 38, 39 |
| CYP2C19 | CYP2C19 Gene-drug variant associations affecting drug response/metabolism include amitriptyline, citalopram, clomipramine, clopidogrel, imipramine, lansoprazole, omeprazole, pantoprazole, sertraline, voriconazole. (CPIC Level best drug: A/ PharmGKB Level Best drug:1A) ) PharmGKB Web site. http://Clinical Guideline Annotations (pharmgkb.org). Accessed November 2nd, 2022. Ref: 40-44. |
| CYP2D6 | CYP2D6 Gene-drug variant associations affecting drug response/metabolism include amitriptyline , atomoxetine, codeine , desipramine, doxepin, fluvoxamine, imipramine, metoprolol, nortriptyline, ondansetron, paroxetine ,risperidone, tamoxifen, tramadol, venlafaxine. (CPIC Level best drug: A/ PharmGKB Level Best drug:1A) PharmGKB Web site. http://Clinical Guideline Annotations (pharmgkb.org). Accessed November 2nd, 2022. Ref: 43-48. |
| CYP3A4 | CYP3A4 Gene-drug variant associations affecting drug response/metabolism (ex. exposure, clearance) include atorvastatin, cyclosporine, oxycodone, quetiapine, simvastatin, tacrolimus. (CPIC Level best drug: C/ PharmGKB Level Best drug:1B)/ Genes-Drugs – CPIC (cpicpgx.org)/PharmGKB Web site. http://Clinical Guideline Annotations (pharmgkb.org). Accessed November 2nd, 2022. |
| CYP3A5 | CYP3A5 Gene-drug variant associations affecting tacrolimus drug dosing requirements/metabolism. (CPIC Level best drug: A/ PharmGKB Level Best drug:1A)/ Genes-Drugs – CPIC (cpicpgx.org)/ CPIC: https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/) PharmGKB Web site. http://Clinical Guideline Annotations (pharmgkb.org). Accessed November 2nd, 2022. |
| F2 | Patients with the Factor ll gene Prothrombin variant may be at an increased risk of blood clot formation (thrombosis) when exposed to other risk factors such as smoking, pregnancy, obesity, oral contraceptive use, and immobility. The risk is approximately 3-10 times higher in individuals who have one copy of the genetic variant. The risk in people who carry two copies of the genetic variant is unknown. Individuals who do not have a Factor II Prothrombin mutation may still be at increased risk. Other changes in the Factor II gene that were not tested for, changes in other genes, and non-genetic factors may still increase a patient’s risk for thrombosis. PharmGKB Web site. http://Clinical Guideline Annotations (pharmgkb.org). Accessed March 22nd, 2023. Ref: 52, 53 |
| F5 | Individuals with the Factor V Leiden gene variant may be at an increased risk of blood clot formation. This risk is approximately 2-10 times higher in individuals who have one copy of the genetic variant, and greater than 10 times higher for individuals who carry two copies of the genetic variant. Individuals who do not have the Factor V Leiden mutation may still be at increased risk. Other changes in the Factor V gene that were not tested for, changes in other genes, and non-genetic factors may still increase a patient’s risk for thrombosis. PharmGKB Web site. http://Clinical Guideline Annotations (pharmgkb.org). Accessed March 22nd, 2023. Ref: 53, 54 |
| MTHFR (both alleles) | The protein encoded by this gene catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine remethylation to methionine. Mutations in this gene are associated with methylenetetrahydrofolate reductase deficiency. Genetic variation in this gene may influence susceptibility to occlusive vascular disease, neural tube defects, cancer. Mental Health: Patients who are homozygous mutant for MTHFR 677 (T/T) genotype may have an increased risk of early onset of schizophrenia, bipolar disorder, and increase in severity of depressive symptoms in depressive disorders. Ethnic populations studied include: African, Asian, Caucasian. Oncology/Rheumatology: Patients with AG or AA genotypes and treated for certain cancers (ex. lymphoma, osteocarcinoma, leukemia) and arthritis (ex. rheumatoid, psoriatic) may be at an increased risk of adverse effects if treated with methotrexate when compared to patients with GG genotype However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of toxicity following methotrexate treatment. Cardiovascular: Individuals who are found to have two mutations of MTHFR may be at an increased risk for serious blood clot formation. Individuals who have only one or no copies of either genetic change in the MTHFR gene may still be at increased risk. Other changes in the MTHFR gene that were not tested for, changes in other genes, and non-genetic factors may still increase a patient’s risk for thrombosis. (CPIC Level best drug: C/ PharmGKB Level Best drug: 2A) (PharmGKB) Ref: 14, 15, 66, 68 |
| VKORC1 | Vitamin K epoxide complex subunit 1 (VKORC1) is the enzyme that activates Vitamin K. Mutations in VKORC1 are associated with deficiencies in vitamin-K-dependent clotting factors. A particular VKORC1 variant (-1639G>A) leads to increased sensitivity to warfarin. VKORC1 mutation accounts for 25-44% of warfarin dose variability and is typically tested for at the same time as 2C9 when warfarin is being considered. Ref: 3, 39 |
References for individual gene-drug interactions are available at EffectiveRX Panel References.
Billing coverage
Patient Costs
How much does the test cost?
Medicare (Part B), Medicare Advantage and Medicaid Covered Tests:
You will have a $0 out-of-pocket cost.
Medicare now covers the cost of EffectiveRX for a wide range of medications. Please refer to our Comprehensive & Neuropsychiatric Medication Lists for more information.
Commercial Insurance and Uninsured:
Patient responsibility varies based on plan terms. Please contact us for an estimate of financial responsibility.
Please contact our billing department at 1-877-890-1444 or via email at hereforyou@genetworx.com for more information.
Contact Us Today
Order now and receive your diagnostic testing supplies within 24 hours.